SOUTH SAN FRANCISCO, CA, USA I February 04, 2025 I SiteOne Therapeutics, Inc., a clinical-stage biopharmaceutical company developing selective ion channel modulators for the treatment of pain, cough, and other conditions involving hyperexcitability of the peripheral nervous system, today announced positive phase 1 clinical trial results for STC-004, its lead Na V 1.8 inhibitor for the non-opioid treatment of pain. “These compelling phase 1 results reinforce the potential of STC-004 as a transfor

Preparing to Initiate Clinical Development in Patients with Hematologic Malignancies in the First Quarter of 2025 Series B Financing Funds AUTX-703 Development through Phase 1 Clinical Proof-of-Concept Expanding KAT2A/B Target Opportunity into Autoimmune Indications NEWTON, MA, USA I February 04, 2025 I Auron Therapeutics , a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease, today announced progress for its lead

– Initiation of Phase 1/2 combination trial with PYX-201, an extracellular ADC targeting Extradomain-B Fibronectin (EDB+FN) and Merck’s KEYTRUDA® (pembrolizumab) in multiple solid tumors – Phase 1 monotherapy trial expanded to include cohorts in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) – Ongoing commitment to innovative cancer therapies for patients with limited treatment options BOSTON, MA, USA I February 04, 2025 I Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-s

CHICAGO, IL, USA I February 04, 2025 I COUR Pharmaceuticals, a clinical-stage biotechnology company developing first-in-class, disease-modifying therapies designed to induce antigen-specific tolerance for immune-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for CNP-103, a nanoparticle in development to address the underlying autoimmunity of Type 1 diabetes (T1D). “Clearance of the IND application for C

Oral and poster presentations highlight FLT201’s potential to set a new standard of care LONDON, UK I February 04, 2025 I Spur Therapeutics today announced data from its Phase 1/2 GALILEO-1 trial of FLT201, an adeno-associated virus (AAV) gene therapy candidate for Gaucher disease type 1, showing rapid and sustained improvements in glucosylsphingosine (lyso-Gb1), one of the best predictors of clinical response in Gaucher disease, as well as improvement or maintenance of blood counts, organ volum

"RFK Jr.'s support is growing, particularly among Moms, America's true frontline healthcare providers." – Dr. Joseph Varon WASHINGTON, Feb. 4, 2025 /PRNewswire/ -- Independent Medical Alliance (IMA) President and Chief Medical Officer, Dr. Joseph Varon, released the following statement today on the Senate Finance Committee vote that recommends RFK Jr. to a full vote of the Senate. "Americans demand a frank conversation about the state of our government healthcare agencies, and we're very gratef

New clinic is the first and only dedicated food allergy office in Westchester County; Led by Dr. Zoya Treyster RYE BROOK, N.Y., Feb. 4, 2025 /PRNewswire/ -- Latitude Food Allergy Care, the leading network of food allergy clinics in the United States, has opened a new location in Westchester County – its third location in the New York area. As part of the opening, Dr. Zoya Treyster, has joined the Latitude medical staff and will lead the clinical team in Westchester. She brings over 15 years of d

Members in all 50 U.S. states can now access virtual visits that are covered by most major insurance, including hormone therapy medications to treat menopause symptoms MENLO PARK, Calif., Feb. 4, 2025 /PRNewswire/ -- Carrot Fertility, the leading global fertility, family-building, and lifelong hormonal healthcare platform, today announced Telemedicine for Menopause. This first-of-its-kind offering functions as a virtual menopause and midlife health clinic, saving members time, reducing costs, an

2月4日，辉瑞公布了2024年业绩。全年营收636.27亿美元，同比增长7%，若排除新冠口服药Paxlovid 和新冠疫苗Comirnaty的影响，营收增长12%。第四季度营收177.63亿美元，同比增长21%。 过去三年中，受新冠产品销售波动影响，辉瑞总营收从2022年的1003亿美元，下跌至2023年的585亿美元（-41%），去年迎来触底反弹，业绩重回正增长。2024年全年研发投入为108.22亿美元，同比增加1%。基于当前财务状况，辉瑞重申了2025年财务指引，公司将再削减5亿美元成本以进一步减轻财务负担。 辉瑞此前重金收购产品组合在2024年收入表现如下。116亿美元收购Biohaven公司所获得的偏头痛药物瑞美吉泮（Nurtec ODT/Vydura），在2024年贡献了12.63亿美元收入，实现强劲增长（+36%），在口服CGRP类药物市场中占有率约达49%。 辉瑞在2023年底以430亿美元收购Seagen所获得多款ADC产品，在2024年贡献了超32亿美元营收。其中Nectin-4 ADC药物Padcev（维恩妥尤单抗）营收达15.88亿美元，CD30 ADC药物Ad

Novel approach designed to offer a more personalized and effective treatment option for patients suffering from diabetes and potentially other diseases. IRVINE, Calif., Feb. 4, 2025 /PRNewswire/ -- GATC Health Corp., a leading tech-bio company leveraging artificial intelligence (AI) to transform drug discovery, announces significant progress in its research to develop a more effective treatment for diabetes. In a comprehensive review article recently published in the American Journal of Biomedic